Adicet Bio (FRA:1IJ) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €6.60
! 3 Warning Signs
View Full Analysis

What is Adicet Bio OCF Margin %?

Adicet Bio FRA:1IJ -5.04% 31 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 957 Biotechnology companies, Adicet Bio ranks worse than 104493.1% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Adicet Bio's Cash Flow from Operations for the three months ended in Mar. 2026 was €-18.59 Mil. Adicet Bio's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Adicet Bio's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Adicet Bio's current OCF Yield % is -116.73%.

The historical rank and industry rank for Adicet Bio's OCF Margin % or its related term are showing as below:


During the past 8 years, the highest OCF Margin % of Adicet Bio was -179.13%. The lowest was -2802.21%. And the median was -232.10%.

FRA:1IJ's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Adicet Bio OCF Margin % Related Terms

Adicet Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Adicet Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio OCF Margin % Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -524.69 -179.13 0.00 0.00 0.00

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Adicet Bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-81.34/0
= %

Adicet Bio's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-18.589/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Adicet Bio (FRA:1IJ) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #999999 out of 957 companies in the Biotechnology industry.
Is Adicet Bio's OCF Margin % too high?
Adicet Bio's current OCF Margin % is 0.00%. Based on the distribution chart, Adicet Bio ranks #999999 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's OCF Margin % compare to EDSA and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 957 companies for OCF Margin %. This places Adicet Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Adicet Bio and its competitors. Adicet Bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Adicet Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price